A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 21, 2023

Primary Completion Date

August 27, 2024

Study Completion Date

August 27, 2024

Conditions
HIV Infections
Interventions
DRUG

VH3739937

VH3739937 will be administered.

DRUG

Placebo

Placebo will be administered.

Trial Locations (18)

1009

GSK Investigational Site, Vitoria-Gasteiz

2000

GSK Investigational Site, Rosario

11407

GSK Investigational Site, Jerez de la Frontera

12462

GSK Investigational Site, Athens

15006

GSK Investigational Site, A Coruña

16132

GSK Investigational Site, Genova

18014

GSK Investigational Site, Granada

20142

GSK Investigational Site, Milan

25123

GSK Investigational Site, Brescia

28006

GSK Investigational Site, Madrid

28222

GSK Investigational Site, Madrid

33136

GSK Investigational Site, Miami

75246

GSK Investigational Site, Dallas

93301

GSK Investigational Site, Bakersfield

C1181ACH

GSK Investigational Site, Buenos Aires

00133

GSK Investigational Site, Roma

01-201

GSK Investigational Site, Warsaw

03010

GSK Investigational Site, Alicante

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY